Bristol-Myers Squibb-Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View

Key Takeaways BMY posted Q2 EPS of $1.46 vs.$ 1.07 estimate, with revenues rising 1% to $12.2B, beating forecasts.Growth Portfolio sales rose 18% to$ 6.6B, led by Opdivo, Breyanzi, Reblozyl and Camzyos.BMY raised 2025 revenue guidance but cut EPS outlook due to IPRD charges from the BNTX partnership.Bristol-Myers Squibb Company ((BMY) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.46, which comfortably beat the Zacks Consensus Estimate of$ 1.07. In the year-ago quarter, BMY posted adju ...